Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients
ObjectiveThe aim of this study was to explore the profile of cytokine changes during the combination therapy with pegylated interferon alpha (PEG-IFN-α) and its relationship with HBsAg loss in nucleos(t)ide analogs (NAs)-suppressed chronic hepatitis B patients.MethodsSeventy-six patients with chroni...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1121778/full |
| _version_ | 1797945478851067904 |
|---|---|
| author | Wen-Xin Wang Rui Jia Xue-Yuan Jin Xiaoyan Li Xiaoyan Li Shuang-Nan Zhou Xiao-Ning Zhang Chun-Bao Zhou Fu-Sheng Wang Fu-Sheng Wang Junliang Fu Junliang Fu |
| author_facet | Wen-Xin Wang Rui Jia Xue-Yuan Jin Xiaoyan Li Xiaoyan Li Shuang-Nan Zhou Xiao-Ning Zhang Chun-Bao Zhou Fu-Sheng Wang Fu-Sheng Wang Junliang Fu Junliang Fu |
| author_sort | Wen-Xin Wang |
| collection | DOAJ |
| description | ObjectiveThe aim of this study was to explore the profile of cytokine changes during the combination therapy with pegylated interferon alpha (PEG-IFN-α) and its relationship with HBsAg loss in nucleos(t)ide analogs (NAs)-suppressed chronic hepatitis B patients.MethodsSeventy-six patients with chronic hepatitis B with HBsAg less than 1,500 IU/ml and HBV DNA negative after receiving ≥ 1-year NAs therapy were enrolled. Eighteen patients continued to take NAs monotherapy (the NAs group), and 58 patients received combination therapy with NAs and PEG-IFN-α (the Add-on group). The levels of IFNG, IL1B, IL1RN, IL2, IL4, IL6, IL10, IL12A, IL17A, CCL2, CCL3, CCL5, CXCL8, CXCL10, TNF, and CSF2 in peripheral blood during treatment were detected.ResultsAt week 48, 0.00% (0/18) in the NAs group and 25.86% (15/58) in the Add-on group achieved HBsAg loss. During 48 weeks of combined treatment, there was a transitory increase in the levels of ALT, IL1RN, IL2, and CCL2. Compared to the NAs group, CXCL8 and CXCL10 in the Add-on group remain higher after rising, yet CCL3 showed a continuously increasing trend. Mild and early increases in IL1B, CCL3, IL17A, IL2, IL4, IL6, and CXCL8 were associated with HBsAg loss or decrease >1 log, while sustained high levels of CCL5 and CXCL10 were associated with poor responses to Add-on therapy at week 48.ConclusionsThe serum cytokine change profile is closely related to the response to the combination therapy with PEG-IFN-α and NAs, and may help to reveal the mechanism of functional cure and discover new immunological predictors and new therapeutic targets. |
| first_indexed | 2024-04-10T20:55:45Z |
| format | Article |
| id | doaj.art-8dbca7dc2b3b4232ab66b13223076819 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T20:55:45Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8dbca7dc2b3b4232ab66b132230768192023-01-23T06:08:25ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011410.3389/fimmu.2023.11217781121778Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patientsWen-Xin Wang0Rui Jia1Xue-Yuan Jin2Xiaoyan Li3Xiaoyan Li4Shuang-Nan Zhou5Xiao-Ning Zhang6Chun-Bao Zhou7Fu-Sheng Wang8Fu-Sheng Wang9Junliang Fu10Junliang Fu11Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Peking University 302 Clinical Medical School, National Clinical Research Center for Infectious Diseases, Beijing, ChinaDepartment of Gastroenterology, The 985th Hospital of Joint Logistic Support Force of Chinese PLA, Taiyuan, ChinaSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Peking University 302 Clinical Medical School, National Clinical Research Center for Infectious Diseases, Beijing, ChinaSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Peking University 302 Clinical Medical School, National Clinical Research Center for Infectious Diseases, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Peking University 302 Clinical Medical School, National Clinical Research Center for Infectious Diseases, Beijing, ChinaSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Peking University 302 Clinical Medical School, National Clinical Research Center for Infectious Diseases, Beijing, ChinaSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Peking University 302 Clinical Medical School, National Clinical Research Center for Infectious Diseases, Beijing, ChinaSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Peking University 302 Clinical Medical School, National Clinical Research Center for Infectious Diseases, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaSenior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Peking University 302 Clinical Medical School, National Clinical Research Center for Infectious Diseases, Beijing, ChinaMedical School of Chinese PLA, Beijing, ChinaObjectiveThe aim of this study was to explore the profile of cytokine changes during the combination therapy with pegylated interferon alpha (PEG-IFN-α) and its relationship with HBsAg loss in nucleos(t)ide analogs (NAs)-suppressed chronic hepatitis B patients.MethodsSeventy-six patients with chronic hepatitis B with HBsAg less than 1,500 IU/ml and HBV DNA negative after receiving ≥ 1-year NAs therapy were enrolled. Eighteen patients continued to take NAs monotherapy (the NAs group), and 58 patients received combination therapy with NAs and PEG-IFN-α (the Add-on group). The levels of IFNG, IL1B, IL1RN, IL2, IL4, IL6, IL10, IL12A, IL17A, CCL2, CCL3, CCL5, CXCL8, CXCL10, TNF, and CSF2 in peripheral blood during treatment were detected.ResultsAt week 48, 0.00% (0/18) in the NAs group and 25.86% (15/58) in the Add-on group achieved HBsAg loss. During 48 weeks of combined treatment, there was a transitory increase in the levels of ALT, IL1RN, IL2, and CCL2. Compared to the NAs group, CXCL8 and CXCL10 in the Add-on group remain higher after rising, yet CCL3 showed a continuously increasing trend. Mild and early increases in IL1B, CCL3, IL17A, IL2, IL4, IL6, and CXCL8 were associated with HBsAg loss or decrease >1 log, while sustained high levels of CCL5 and CXCL10 were associated with poor responses to Add-on therapy at week 48.ConclusionsThe serum cytokine change profile is closely related to the response to the combination therapy with PEG-IFN-α and NAs, and may help to reveal the mechanism of functional cure and discover new immunological predictors and new therapeutic targets.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1121778/fullchronic hepatitis BcytokineCXCL-10HBsAg losscombined treatmentPeg-IFN-α |
| spellingShingle | Wen-Xin Wang Rui Jia Xue-Yuan Jin Xiaoyan Li Xiaoyan Li Shuang-Nan Zhou Xiao-Ning Zhang Chun-Bao Zhou Fu-Sheng Wang Fu-Sheng Wang Junliang Fu Junliang Fu Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients Frontiers in Immunology chronic hepatitis B cytokine CXCL-10 HBsAg loss combined treatment Peg-IFN-α |
| title | Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients |
| title_full | Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients |
| title_fullStr | Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients |
| title_full_unstemmed | Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients |
| title_short | Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients |
| title_sort | serum cytokine change profile associated with hbsag loss during combination therapy with peg ifn α in nas suppressed chronic hepatitis b patients |
| topic | chronic hepatitis B cytokine CXCL-10 HBsAg loss combined treatment Peg-IFN-α |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1121778/full |
| work_keys_str_mv | AT wenxinwang serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT ruijia serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT xueyuanjin serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT xiaoyanli serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT xiaoyanli serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT shuangnanzhou serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT xiaoningzhang serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT chunbaozhou serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT fushengwang serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT fushengwang serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT junliangfu serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients AT junliangfu serumcytokinechangeprofileassociatedwithhbsaglossduringcombinationtherapywithpegifnainnassuppressedchronichepatitisbpatients |